UMIN-CTR Clinical Trial

BACK TOP
UMIN-CTR English Home Glossary (Simple) FAQ Search clinical trials

Name:
UMIN ID:

Recruitment status Open public recruiting
Unique ID issued by UMIN UMIN000031903
Receipt No. R000036427
Scientific Title Switching to tenofovir alafenamide on efficacy, safety, and tolerability for nucleos(t)ide analogue-experienced patients with chronic hepatitis B
Date of disclosure of the study information 2018/03/26
Last modified on 2018/03/26

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Switching to tenofovir alafenamide on efficacy, safety, and tolerability for nucleos(t)ide analogue-experienced patients with chronic hepatitis B
Acronym Effectiveness for switiching to tenofovir alafenamide
Scientific Title Switching to tenofovir alafenamide on efficacy, safety, and tolerability for nucleos(t)ide analogue-experienced patients with chronic hepatitis B
Scientific Title:Acronym Effectiveness for switiching to tenofovir alafenamide
Region
Japan

Condition
Condition Chronic hepatitis B
Classification by specialty
Hepato-biliary-pancreatic medicine
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To investigate efficacy, safety, and tolerability after switching from other nucleos(t)ide analogues to TAF for nucleos(t)ide analogue-experienced Japanese patients with chronic hepatitis B
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase Not applicable

Assessment
Primary outcomes Proportion of patients with virological response (HBV DNA level <2.1 log copies/mL) at weeks 24, 48, 96, 120 and 144 after switching from other nucleos(t)ide analogues to TAF
Key secondary outcomes 1.Changes from the baseline in hepatitis surface antigen levels
2.Changes from the baseline in serum alanine aminotransferase
3.Changes from the baseline in estimated glomerular filtration rate and urine beta-2 microglobulinuria
4.Changes from the baseline in albuminuria
5.Changes in spine-and hip-bone mineral density

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1.Patients with chronic hepatitis B and under treatment by nucleos(t)ide analogue(s) (lamivudine (LMV), adefovir dipivoxil (ADV), entecavir (ETV), and tenofovir disoproxil fumarate (TDF)), including compensated cirrhosis.
2.Patients with stable and well controlled hypertension, diabetes mellitus, heart diseases, CKD or risk of CKD (eGFR <60), and other patients whom Dr. consider appropriate to switch.
Key exclusion criteria 1.Patients with decompensated cirrhosis
2.Patients with co-infection of hepatitis C virus
3.Patients with co-infection of human immunodeficiency virus
4.Patients with stable estimated glomerular filtration rate <15 mL/min/1.73 m2
5.Patients with albumin <30 g/L and platelets <30,000
6.Patients with autoimmune hepatitis
7.Constant heavy alcohol drinkers (converted to ethanol over 60 g/day)
8.Patients who are pregnant females, or females who may become pregnant, or females who are breastfeeding
9.Patients judged (by the physician in charge of research) to be inappropriate as subjects for the study for any other reasons
Target sample size 400

Research contact person
Name of lead principal investigator
1st name
Middle name
Last name Norihiro Furusyo
Organization Kyushu University Hospital
Division name Kyushu University Liver Disease Study (KULDS)
Zip code
Address 3-1-1, Maidashi, Higashi-ku, Fukuoka
TEL 092-642-5909
Email furusyo@gim.med.kyushu-u.ac.jp

Public contact
Name of contact person
1st name
Middle name
Last name Eiichi Ogawa
Organization Kyushu University Hospital
Division name Department of General Internal Medicine
Zip code
Address 3-1-1, Maidashi, Higashi-ku, Fukuoka
TEL 092-642-5909
Homepage URL
Email eogawa@gim.med.kyushu-u.ac.jp

Sponsor
Institute Kyushu University
Institute
Department

Funding Source
Organization Gilead Sciences K.K.
Organization
Division
Category of Funding Organization Profit organization
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization
Address
Tel
Email

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2018 Year 03 Month 26 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Open public recruiting
Date of protocol fixation
2018 Year 03 Month 26 Day
Date of IRB
Anticipated trial start date
2018 Year 03 Month 26 Day
Last follow-up date
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information None

Management information
Registered date
2018 Year 03 Month 26 Day
Last modified on
2018 Year 03 Month 26 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000036427

Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name


Contact us.